NASDAQ TNXP

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) is down 12% in a month after announcing a research collaboration expansion with Columbia University. This research partnership focuses on the study of immune response to COVID-19 in healthy subjects that are asymptomatic or have recovered from the virus. Equally, it will study in vitro antibody and T cell responses to the COVID-19 causing virus, SARS-CoV-2.Most importantly, the research seeks to fill vital gaps in…

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) is a clinical-stage biopharma corporation that recently announced that the FDA (Food and Drug Administration) had given them an official written response from the pre-IND (Investigational New Drug) Type B meeting to develop its TNX-1800 product (live vaccine, recombinant horsepox) as a potential COVID-19 vaccine. Tonix Pharmaceuticals believes the response will provide the company with a path to several other agreements on the overall…

In recent weeks, Tonix Pharmaceuticals (NASDAQ:TNXP) has been in the middle of a fair bit of trouble and it has been reflected in the price action in its stock as well. The death spiral in the Tonix stock came about due to the massive setback in the interim analysis from the late stage clinical trials of one of its products. As a matter of fact, most experts believe that the…

Investors of Tonix Pharmaceuticals (NASDAQ:TNXP) investors are not in the best state this week with devastating interim analysis from a  late-stage clinical trial likely to fail, the stock price has plummeted below $1. The firm’s late-stage programs infamously aim at hard conditions like post-traumatic stress disorder and Alzheimer’s disease, the firm is quite weak. Yet, daring investors may be looking at positive signs in the downturn. The company on July…

Tonix Pharmaceuticals (NASDAQ:TNXP) stock is having a rough week after releasing a disappointing preliminary analysis from a late-stage clinical study that seems set to fail. The stock has since plunged below $1.Considering that Tonix’s other late-stage studies focus on difficult to treat conditions such as Alzheimer’s disease and PTSD, its outlook looks frail. However, bold investors may see the stumble as a chance to buy in, and they could be…

Based in New York, Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP). is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800.However, recently the entire company is appearing quite fragile. The company has recently reported that it would not register any new patients with fibromyalgia with respect…

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has appointed Carolyn Taylor as a board member effective July 16, 2021.  Tonix appoints Carolyn Taylor to its Board.  Taylor has been a Covington & Burling law firm partner for over 15 years and has served as General Counsel of Longitude Inc. and Strike Protocols. She said, “It’s a pleasure to join a company with a strong sense of purpose coupled with such a…